Yamagishi became the CEO at KII’s establishment in December 2015. Prior to joining KII, he served as an editor at Nikkei BP, Editor-in-Chief for CNET Japan, and was a co-founder of GREE, Inc., where he served for 10 years as an executive vice president and a director of the board, overseeing the business divisions. He is currently a part-time GREE company director. Graduate of the Keio University Faculty of Economics.
Kinoshita joined KII as a Corporate Officer in April 2016. Prior to joining KII, he served as a capitalist at JAFCO for 24 years and supervised the Investment Division as an executive officer. He has over 20 IPO achievements in various fields and projects including entrepreneurial investment, business revitalization, IT conversion of existing businesses, and more. Graduate of the Waseda University Faculty of Commerce.
Hongo joined KII as a corporate officer in May of 2016. Prior to joining KII, he served in Summit Pharmaceutical International’s VC operations, overseeing investments in bio-ventures, and was engaged in domestic sales for overseas bio-ventures. Graduate of the Nagoya University Graduate School of Engineering. Doctor of Biomechanical Engineering.
Takaoka joined KII as a Corporate Officer in May 2018. Throughout his 24-year career at Nomura Securities, he was involved in regional venture support, serving as a branch manager in Kashiwa, Mito, Nagoya Ekimae, Tokushima, and more, while also serving as the head of the HR Planning Division at the head office. Graduate of the Keio University Faculty of Economics.
Kawai joined KII in April 2018. Prior to joining KII, he was engaged in research and development of biopharmaceuticals at Astellas Pharma. Graduate of the Osaka University Graduate School of Pharmaceutical Sciences. Pharmacist.
Yamashita joined KII in March 2017. Prior to joining KII, he was involved in underwriting review and principal investment at Daiwa Securities. Graduate of the Keio University Faculty of Economics.